Finland's Medix Biochemica prevails in PROM (premature rupture of foetal membrane) test patent spat with N-Dia
This article was originally published in Clinica
Executive Summary
Finnish rapid test developer Medix Biochemica has won the first round in its legal wrangle with US company N-Dia concerning the infringement of patents related to diagnostic methods and test kits for detecting premature rupture of foetal membrane (PROM).